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Abstract 
Background: Patients with prostate cancer is commonly diagnosed with bone metastases. With the growing use of 
prostate-specific antigen testing, the frequency of prostate cancer has progressively increased in patients younger 
than 70 years. Radiotherapy is recognized for its effect on local control of bone metastases, but whether it could pro-
long overall survival is still controversial.
Methods: A total of 113 prostate cancer patients (<70y) with bone metastases were retrospectively analyzed. The 
Kaplan–Meier method was used for survival analysis with log-rank test. Multivariate analysis was performed to find the 
prognostic factors with the COX regression model.
Results: The 1-, 2-, 3-, 5-, 7- and 10-year survival rates were 97.14, 82.86, 62.61, 38.76, 25.83 and 13.84 % respectively in 
the radiotherapy group, and 92.75, 73.91, 54.66, 36.63, 26.03 and 17.85 % respectively in the non-radiotherapy group, 
which showed no significant difference. Multivariate COX regression showed the overall survival was associated with 
alkaline phosphatase when bone metastases occurred and the number of bone metastases.
Conclusion: With the advances in life-prolonging treatment of metastatic prostate cancer, radiotherapy may not be 
the first choice for young bone metastatic prostate cancer patients in order to improve survival.
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Background
Prostate cancer (PCa) is the most commonly diagnosed 
malignant tumor among males in developed countries 
and the second leading cause of cancer-related mortality 
[1]. Although PCa is usually considered as a disease of 
advanced age, its frequency has progressively increased 
in patients younger than 70 years with the growing use 
of prostate-specific antigen (PSA) testing [2]. Autopsy 
series on patients with PCa reveal that 80–85 % of them 
have bone metastasis, with the pelvis and the vertebrae 
being involved in nearly all cases [3]. Although PCa 
prefers to metastasize to skeleton, patients with PCa in 
whom bone metastasis develops have a relatively good 
survival prognosis, which may even be a few years. 
Therefore, local control of bone metastasis for patients 
with prostate cancer is more important than patients 
with other cancers.
Radiotherapy (RT) is considered as an effective treat-
ment for local control of bone metastasis, which could 
reduce the skeletal-related events (SREs) [4, 5]. It is esti-
mated that the mean cost for RT on bone metastases is as 
high as 7553 USD per episode in the United States, which 
has become a heavy burden for national health care sys-
tem [6]. However, the long-term effect of RT on bone 
metastases is still controversial. In this retrospective 
study, we reviewed 113 young PCa patients (<70y) who 
had bone metastasis. Patients’ characteristics, treatment 
efficacy, and prognosis were analyzed. The result revealed 
that RT on bone metastases cannot prolong overall sur-
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Patients and methods
Patient collection
A total of 113 patients (<70y) with bone metastases from 
PCa who were treated between 1997 and 2012 at Zhong-
shan Hospital, Fudan University, were included. All of the 
patients were confirmed with primary PCa by pathologi-
cal diagnosis and were diagnosed with bone metastasis 
through radioisotope scanning or magnetic resonance 
imaging.
Collection of clinic pathological data
Patient age at diagnosis, Gleason score at initial diagno-
sis, treatment for primary prostate lesions, number of 
bone lesions, PSA and alkaline phosphatase (ALP) lev-
els, organ metastases sites, regional and remote lymph 
node metastases, as well as follow-up duration and sur-
vival status, were retrospectively collected and reviewed. 
Serum PSA and ALP values were determined in the 
department of clinical laboratory of Zhongshan Hospi-
tal. The PSA values of the patients were characterized as 
0–4 ng/ml, 4–20 ng/ml or more than 20 ng/ml, while the 
ALP values were characterized as less than 150 U/l, equal 
or more than 150 U/l. In the pathological examinations of 
the patients, Gleason scores were characterized as 2–4, 
5–7 or 8–10. When determining the number of metas-
tases by radioisotope scanning, the number of metasta-
ses in each vertebra and rib was calculated as one; in the 
statistical evaluation, the number of bone metastases was 
assessed as either single or multiple.
Radiotherapy for bone metastases
Indications of RT for bone metastases included pain, risk 
of pathologic fracture, and neurologic complications aris-
ing from spinal cord compression and nerve root pain. 
For patients with multiple bone metastases, those with 
lesions causing pain or possibly spinal cord compression 
were first considered for RT. Bone metastatic status was 
recorded at the initial RT session for metastatic bone 
disease. Irradiation was delivered through a single pos-
terior field or parallel opposed fields, depending on the 
location and depth of lesions according to CT or MRI. 
The majority of therapy was provided with 6-megavolt 
(MV) or 15-MV photons; however, electron therapy was 
also selected for those with shallow lesions such as in the 
ribs or skull, or extremity metastases. Radiation fields 
involved macroscopic tumor volume and 1 to 1.5  cm 
margins. In the case of vertebral bone metastases, radia-
tion fields usually encompassed 1 normal vertebra above 
and below the metastatic lesions. If the lesions presented 
with soft-tissue extension concurrence, the radiation 
fields were enlarged on the basis of CT or MRI results. 
We scheduled the full radiation dosage at 46 Gy for the 
vertebral metastatic lesions and 50–60 Gy for soft-tissue 
concurrence beyond the spinal cord, in daily doses of 
2 Gy/fraction, 5 times a week. However, factors that indi-
cated the need for a reduced dose were considered, such 
as progressive primary disease, many lesions, poor Kar-
nofsky performance status, adverse effects, and patient 
inconvenience during RT.
Follow‑up and statistical methods
There were 5 in the non-RT group and 4 patients in the 
RT group lost to follow-up. The survival time was defined 
as from the date the first diagnosis of bone metastases to 
the date of death or of the last follow-up. The univariate 
and multivariate analyses were performed using SPSS 
18.0 software (IBM, Armonk, NY, USA). The Kaplan–
Meier method with a log-rank test was used for survival 
rate calculations and to evaluate each variable. Multi-
variate analysis was carried out with the Cox regres-
sion model, and all of the variables were analyzed with 
the method “enter”. All of the tests were two-sided, and 
p < 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 104 patients (92.0  %) were followed up until 
the date of death or 30 June 2015. The average follow-up 
time for all patients was 50.01 months (SD = 32.94) while 
the median was 41 months (range from 1 to 177 months). 
All of the patients received endocrine therapy, includ-
ing surgical castration, androgen ablation, or maximal 
androgen blockade. Among them, 35 patients received 
radiotherapy on bone metastases and 69 patients did 
not. The age, Gleason score, PSA level, ALP level, rate of 
receiving chemotherapy, the number of bone metastases, 
or other organ metastasis showed no significant differ-
ence between the RT and non-RT group. Only the rate 
of regional node metastasis showed significant difference. 
The baseline characteristic data are shown in Table 1.
Bone metastasis sites
Vertebrae, ribs and pelvises were the most common 
metastasis sites in PCa patients. Figure  1 shows bone 
metastatic sites in patients.
Survival rate analysis
From the diagnosis of bone metastases, the 1-, 2-, 3-, 5-, 
7- and 10-year survival rates were 97.14, 82.86, 62.61, 
38.76, 25.83 and 13.84  % respectively in the RT group, 
and 92.75, 73.91, 54.66, 36.63, 26.03 and 17.85 % respec-
tively in the non-RT group. The survival rate of RT and 
non-RT group showed no significant difference (Table 2 
and Fig. 2).
As the significant difference of regional lymph node 
metastasis between RT and non-RT group, stratified 
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Table 1 Baseline characteristics of patients
PSA prostate-specific antigen; ALP alkaline phosphatase; RT radiotherapy
RT Non‑RT P value
Age 64.26 ± 4.98 63.96 ± 5.48 0.788
Gleason score 7.91 ± 1.31 7.88 ± 1.33 0.913
PSA 323.05 ± 529.83 368.14 ± 613.40 0.713
ALP 304.32 ± 455.35 316.52 ± 346.32 0.884
Chemotherapy 0.162
 Yes 9 (25.71 %) 10 (14.49 %)
 No 26 (74.29 %) 59 (85.51 %)
The number of bone metastases 0.975
 Single 6 (17.14 %) 12 (17.39 %)
 Multiple 29 (82.86 %) 57 (82.61 %)
Regional lymph node metastasis 0.002
 Yes 1 (2.86 %) 20 (28.99 %)
 No 34 (97.14 %) 49 (71.01 %)
Other organ metastasis 0.09
 Yes 7 (20.00 %) 25 (36.23 %)
 No 28 (80.00 %) 44 (63.77 %)
Fig. 1 Sites of bone metastases from PCa in RT and non-RT group. PCa prostate cancer; RT radiotherapy
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analysis was performed. When adjusted for this factor, 
there was still no significant difference between the RT 
and non-RT groups (Table 3).
Prognostic factor analysis
The univariate analysis of the results indicated that the 
survival was associated with ALP when bone metastases 
occurred, the number of bone metastases, and regional 
lymph node metastases when bone metastases occurred 
(p < 0.05). The differences for other factors were not sta-
tistically significant (p > 0.05, Table 2 and Fig. 2).
Multivariate Cox regression analysis indicated that ALP 
when bone metastases occurred and the number of bone 
metastases were significant factors of survival, while the 
radiotherapy was not. The coefficient of regression and 
relative risk were showed in Table 4.
Discussion
The clinical features of bone metastases from PCa are 
similar with other malignancies in which bone metas-
tases most commonly affect the axial skeleton [7]. The 
most common metastatic sites are the vertebrae, ribs 
and pelvis. RT is one of the most important therapeutic 
options available in advanced PCa stage. Its effects have 
been recognized for local control of bone metastases and 
reducing the SREs. However, when it comes to the long-
term prognosis of RT for PCa bone metastases, it is still 
controversial [8–11].
Conventionally, RT is just a palliative treatment for 
advanced PCa patients with much lower doses to destroy 
the tumor cells. The exact mechanism of palliative RT has 
not been well defined, which may be the effects on bone 
homeostasis or alteration of signaling pathways [8, 12]. 
Table 2 Univariate analysis for survival
ALP alkaline phosphatase; PSA prostate-specific antigen
a  Defined as an organ around with prostate, such as the bladder, spermatophores, urethra and rectum
b  Defined as brain, lung and liver metastases





1 year 2 years 3 years 5 years 7 years 10 years
Radiotherapy on metastasis sites 0.817
 With 35 97.14 82.86 62.61 38.76 25.83 13.84 66.1 54
 Without 69 92.75 73.91 54.66 36.63 26.03 17.85 59.4 46
Chemotherapy 0.875
 With 19 94.74 78.95 68.42 38.6 20.58 20.58 62.3 53
 Without 85 94.12 76.47 54.76 36.82 26.48 15.61 65.2 46
Gleason scores when diagnosed as PCa 0.564
 2–4 1 100.00 100.00 100.00 100.00 0.00 0.00 79.0 79
 5–7 31 100.00 90.32 57.45 42.79 28.53 23.77 75.5 45
 8–10 72 91.67 70.83 56.66 33.80 24.96 11.88 55.0 49
PSA when bone metastases occurred 0.692
 <4 ng ml−1 7 85.71 71.43 71.43 42.86 28.57 14.29 61.4 54
 4–20 ng ml−1 10 90.00 80.00 70.00 45.00 45.00 22.50 78.6 58
 >20 ng ml−1 87 95.40 77.01 54.71 35.74 23.36 15.73 58.1 45
ALP when bone metastases occurred 0.020
 <150 U I−1 51 96.09 82.35 64.4 45.6 33.74 24.78 78.6 57
 ≥150 U I−1 53 82.45 71.70 50.8 28.16 15.08 0.00 46.7 40
The number of bone metastases 0.006
 Single 18 100 94.44 77.78 66.67 49.38 39.51 104.8 84
 Multiple 86 93.02 73.26 53.07 30.46 20.35 10.97 53.1 40
Regional lymph node metastases 0.011
 With 21 90.48 57.14 28.57 21.43 21.43 10.71 71.0 54
 Without 83 95.18 81.93 64.82 41.60 27.51 17.59 42.9 31
Metastases when bone metastases occurred 0.588
 Without 72 98.61 80.56 59.35 38.29 25.54 17.69 69.5 52
 Neighbouring organsa 23 78.26 65.22 51.51 32.78 27.31 – 47.9 43
 Distant organsb 9 100.00 77.78 55.56 41.67 – – 44.3 53
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Comparing with the radical prostatectomy, which dose is 
recommended for greater than 70  Gy, the procedure of 
palliative RT is commonly a single-fraction dose (4–8 Gy) 
or multi-fraction higher doses (20–45 Gy) [8–10, 13]. In 
our study, the full radiation dose for the patients is 46 Gy, 
and part of the patients had less dose due to side effects 
and other reasons. It is demonstrated that the dosage 
and schedule of RT is associated with the overall sur-
vival of PCa patients with bone metastasis. Tabata et al. 
[11] had shown that the oligometastases and oligo recur-
rence of bone metastases in PCa patients treated with 
Fig. 2 The overall survival curves of patients with Kaplan–Meier estimator, tested with a log-rank test. a The overall survival curves of RT and non-RT 
groups, p = 0.817. b The overall survival curves of CT and non-CT groups, p = 0.875. c The overall survival curves of patients with different levels of 
Gleason scores, p = 0.564. d The overall survival curves of patients with different levels of PSA, p = 0.692. e The overall survival curves of patients 
with different levels of ALP, p = 0.020. f The overall survival curves of patients with single or multiple bone metastases, p = 0.006. g The overall 
survival curves of patients with or without metastases of reginal lymph nodes, p = 0.011. h The overall survival curves of patients with or without 
metastases of other organs, p = 0.588. RT radiotherapy; CT chemotherapy; PSA prostate-specific antigen; ALP alkaline phosphatase
Table 3 Stratified analysis of radiotherapy












 RT 1 2.0 2 0.596
 Non-RT 20 45.0 31
Without
 RT 34 68.0 54
 Non-RT 49 63.5 57
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conventional RT doses of >40  Gy had a superior 3-year 
survival compared with those treated with <40 Gy (90.5 
vs 50.0 %, p = 0.012). Wu et al. had also indicated that the 
long-course RT (37.5 Gy in 15 fractions, 40 Gy in 20 frac-
tions, or 50 Gy in 25 fractions) had a better 3-year over-
all survival than short-course RT (20  Gy in 5 fractions 
or 30  Gy in 10 fractions) in bone oligometastases PCa 
patients underwent RT combined with endocrine therapy 
after curative RT for PCa (76.4 vs 44.1 %, p = 0.03) [14]. 
In our study, that the survival between RT and non-RT 
group showed no significant difference may be the result 
of insufficient dose of RT.
Another critical factor that influences the result is the 
sites for RT. As mentioned in methods, for patients with 
multiple bone metastases, those with lesions causing pain 
or possibly spinal cord compression were first considered 
for RT. Not all lesions received radiation so that it might 
influence the long-term survival. To have better effect 
on the diffuse lesions, radionuclides were introduced for 
the treatment to bone metastatic cancer. Several radio-
nuclides have shown effects on the relief of SREs, like 
strontium-89, samarium-153 and radium-223. Among 
them, radium-223 is the most promising radionuclide 
that could improve the survival [15]. Radium-223 is a 
bone-seeking calcium mimetic, which selectively binds 
to areas of increased bone turnover in bone metasta-
ses, and emits high-energy alpha particles of short range 
(<100  µm) [16]. A phase 3, randomized, double-blind, 
placebo-controlled study conducted by Parker et al. [17] 
showed that radium-223 significantly improved overall 
survival of bone metastatic PCa patients compared with 
placebo (14.0 months vs. 11.2 months; HR 0.70; 95 % CI 
0.55–0.88; p = 0.002). The study was terminated for effi-
cacy at the interim analysis and the result was published 
on the NEJM.
In our study, the number of bone metastases, the ALP 
when bone metastases occurred and regional lymph 
node metastases were the prognostic factors analyzed 
by univariate analysis. When adjusting for confound-
ing variables, only the number of bone metastases and 
the ALP when bone metastases occurred had significant 
difference. The number of bone metastases had a strong 
impact on the survival, which was in agreement with 
previous studies. Singh et al. [18] reported that patients 
with five or less metastatic lesions had higher 5-year 
overall survival compared with those with five lesions (73 
vs 45  %), which was similar to metastasis-free patients. 
Schick et  al. reported a 3-year biochemical recurrence-
free survival of 66.5 % in patients treated with androgen 
deprivation combined with high-dose RT for only one 
metastatic lesion and 36.4 % (p = 0.031) in those treated 
for more than one metastases [19]. Similarly, another 
study by Wu et al. [14] showed that significantly improved 
three-year overall survival was observed in PCa patients 
with one metastatic lesion compared with patients with 
more than one metastatic lesions (78.8 vs 42.2  %). For 
patients with single or limited bone metastases, they 
may get better prognosis with aggressive RT. Therefore, 
Hellman and Weichselbaum firstly hypothesized that 
the local treatment of patients with limited number of 
metastatic or recurrent lesions, using surgical resection 
and RT, improved systemic control. In this situation, the 
number of metastases was less than five, and the primary 
lesion could be controlled [20]. It further arose the view-
point for restaging the stage IV cancer. Rubin suggested 
amending the TNM staging system, modifying the “M” to 
represent solitary metastasis (M1), oligometastases (M2), 
or multiple metastases (M3) [21]. For oligometastases of 
PCa, it means a controlled or controllable primary lesion 
with five or fewer metastases (ideally 1–3) located in the 
bone (preferably the spine, or ganglions) [22]. With a few 
retrospective studies, it was suggested that local therapy 
to a small number of gross metastatic sites and recur-
rences might result in prolonged survival or even cure 
[14, 19, 20, 22, 23]. Several phase II prospective clinic 
trials are seeking for more convincing evidence for the 
treatment to oligometastases of PCa [22, 24].
With the advances in the treatment of metastatic 
PCa, the viewpoint has changed from palliative treat-
ment to life-prolonging treatment. Several agents have 
shown effects on the improvement of survival for meta-
static PCa patients, including docetaxel with prednisone, 
Table 4 Multivariate analysis for survival
ALP alkaline phosphatase; β coefficient of regression; PCa prostate cancer; RR 
relative risk; s.e. standard error
a  Gleason 8–10 used as control group
b  PSA > 20 ng ml-1 used as control group
c  Distant organs used as control group
Factors β S.e. RR P value
Radiotherapy on metastasis sites 0.209 0.289 1.233 0.469
Chemotherapy −0.198 0.316 0.820 0.530
Gleason scores when diagnosed as Pcaa 0.876
 2–4 −0.507 1.037 0.602 0.625
 5–7 −0.054 0.277 0.948 0.846
PSA when bone metastases occurredb 0.569
 <4 ng ml−1 0.492 0.475 1.635 0.301
 4–20 ng ml−1 0.214 0.489 1.239 0.661
ALP when bone metastases occurred 0.461 0.251 1.586 0.041
The number of bone metastases 0.889 0.410 2.433 0.030
Regional lymph node metastases 0.580 0.321 1.786 0.071
Metastases when bone metastases 
occurredc
0.957
 Without −0.108 0.443 0.897 0.807
 Neighbouring organs −0.050 0.511 0.951 0.922
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cabazitaxel with prednisone, Sipuleucel-T, abiraterone 
with prednisone, enzalutamide and radium-223 [25]. 
In order to prolong the survival of the metastatic PCa 
patients, radiotherapy may not be the first choice. How-
ever, for palliative treatment only, single fraction of RT is 
still considered as an effective and cost-effective method 
[5, 26, 27]. Therefore, the choice of treatment strategy 
should be considered thoroughly based on the state of 
the patients and the objective of the treatment.
Conclusion
In conclusion, RT on the bone metastases cannot prolong 
the overall survival of young PCa patients. The number 
of bone metastases and the ALP when bone metastases 
occurred are the prognostic factors. In order to improve 
the survival of metastatic PCa patients, RT may not be 
the first choice.
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